BridgeBio reports successful achievement of primary endpoint in Phase 3 study of encaleret.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 29 2025
0mins
Should l Buy BBIO?
Study Overview: BridgeBio Pharma announced positive topline results from its global Phase 3 study, CALIBRATE, which evaluated the efficacy and safety of encaleret for treating autosomal dominant hypocalcemia type 1.
Efficacy Results: The primary endpoint was met, with 76% of participants on encaleret achieving target serum and urine calcium levels, compared to only 4% while on conventional therapy.
Safety Profile: Encaleret was well-tolerated among participants, with no discontinuations related to the study drug reported.
Investigational Drug: Encaleret is an orally-administered, negative allosteric modulator of the calcium-sensing receptor, representing a new treatment approach for this condition.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BBIO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BBIO
Wall Street analysts forecast BBIO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BBIO is 87.63 USD with a low forecast of 69.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Analyst Rating
17 Buy
0 Hold
0 Sell
Strong Buy
Current: 63.730
Low
69.00
Averages
87.63
High
100.00
Current: 63.730
Low
69.00
Averages
87.63
High
100.00
About BBIO
BridgeBio Pharma, Inc. is a biopharmaceutical company. It discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. It also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
U.S. Markets End Thursday in Decline; Estee Lauder Experienced the Largest Drop
- Stock Market Decline: U.S. stock indexes experienced a drop on Thursday, with the overall market declining by 1.59%.
- Sector Performance: The S&P 500 index fell by 1.23%, while another index decreased by 1.20%.
See More
NASDAQ 100 Pre-Market Indicator Rises 126.58 to 25,673.66
- Active Stocks: ImmunityBio, Inc. (IBRX) rises by 0.5199 to $4.47 in pre-market trading with a volume of 15,815,869 shares, indicating investor confidence in its future performance.
- Strong ETF Performance: ProShares UltraPro QQQ (TQQQ) increases by 0.6799 to $55.06 with 3,426,778 shares traded, reflecting a 214.63% rise from its 52-week low, showcasing strong demand for tech stocks.
- Individual Stock Outlook: Micron Technology, Inc. (MU) climbs 16.9056 to $353.54 with a volume of 1,816,774 shares, with an expected EPS of $8.18 for the fiscal quarter ending February 2026, indicating improved earnings forecasts.
- Analyst Rating Insights: AT&T Inc. (T) declines by 0.0516 to $23.68 with 2,123,037 shares traded, and Zacks reports its current mean recommendation is in the 'buy range', suggesting analysts are optimistic about its future performance.
See More
BridgeBio Pharma Prices $550M Convertible Notes Offering with $538.4M Net Proceeds Expected
- Offering Size: BridgeBio Pharma has successfully priced a $550M offering of 0.75% convertible senior notes, expected to close on January 21, 2026, indicating strong demand in the capital markets.
- Conversion Terms: Each $1,000 note can be converted into 9.0435 common shares at a conversion price of approximately $110.58, representing a 45% premium over the last closing price of $76.26 on January 15, 2026, providing an attractive option for investors.
- Use of Proceeds: The company plans to utilize approximately $538.4M in net proceeds to repurchase or repay part of its 2.50% convertible notes due 2027, as well as for general corporate purposes including working capital and capital expenditures, enhancing financial flexibility.
- Market Strategy: While targeting over 30% market share for Attruby, BridgeBio Pharma continues to advance its late-stage pipeline, demonstrating ongoing growth potential in the biopharmaceutical sector.
See More
BridgeBio Pharma Prices $550 Million Convertible Notes Offering
- Financing Size: BridgeBio Pharma announced a $550 million offering of 0.75% convertible senior notes, expected to close on January 21, 2026, indicating an active financing strategy in the capital markets.
- Additional Option: The company granted initial purchasers an option to buy an additional $82.5 million in notes, enhancing financing flexibility and potentially supporting future capital needs.
- Use of Net Proceeds: The estimated net proceeds of approximately $538.4 million will be used to repurchase a portion of the 2.50% convertible senior notes due 2027 and for general corporate purposes, reflecting the company's focus on debt management.
- Stock Buyback Plan: BridgeBio intends to use about $82.5 million in cash to repurchase approximately 1.1 million shares of common stock, aimed at enhancing shareholder value and optimizing capital structure, demonstrating confidence in its stock.
See More
BridgeBio Pharma Prices $550 Million Convertible Notes at 0.75% Interest Rate
- Financing Size: BridgeBio Pharma announced the pricing of $550 million in 0.75% convertible notes, expected to close on January 21, 2026, aimed at reducing interest expenses and extending debt maturity.
- Use of Proceeds: The company plans to utilize approximately $538.4 million in net proceeds to repurchase a portion of its 2.50% convertible notes due 2027, enhancing financial flexibility and reducing future dilution risks.
- Share Repurchase Plan: BridgeBio will use about $82.5 million in cash to repurchase approximately 1.1 million shares of common stock, which is expected to boost market prices and may influence the initial conversion price of the notes.
- Conversion Terms: The initial conversion price of the notes is approximately $110.58 per share, representing a 45% premium over the last reported price on January 15, 2026, providing holders with potential capital appreciation opportunities.
See More
BridgeBio Pharma (BBIO) Plans $550 Million Convertible Notes Offering
- Financing Plan: BridgeBio Pharma announced its intention to privately place $550 million of convertible senior notes with qualified institutional buyers, with initial purchasers expected to receive an additional $82.5 million option, thereby enhancing the company's capital structure and liquidity.
- Use of Proceeds: The net proceeds from this offering are intended for repurchasing, settling conversion obligations related to its 2.50% convertible senior notes due 2027, and for general corporate purposes, indicating the company's focus on debt management.
- Share Buyback: BridgeBio also plans to use up to $82.5 million of cash on hand to repurchase shares from certain note purchasers, demonstrating proactive measures in capital allocation to enhance shareholder value.
- Market Reaction: Following the announcement, BridgeBio's stock fell 4.00% in after-hours trading to $74.64, reflecting a cautious market sentiment regarding the financing plan, which may impact investor confidence.
See More
U.S. Markets End Thursday in Decline; Estee Lauder Experienced the Largest Drop
- Stock Market Decline: U.S. stock indexes experienced a drop on Thursday, with the overall market declining by 1.59%.
- Sector Performance: The S&P 500 index fell by 1.23%, while another index decreased by 1.20%.
See More
NASDAQ 100 Pre-Market Indicator Rises 126.58 to 25,673.66
- Active Stocks: ImmunityBio, Inc. (IBRX) rises by 0.5199 to $4.47 in pre-market trading with a volume of 15,815,869 shares, indicating investor confidence in its future performance.
- Strong ETF Performance: ProShares UltraPro QQQ (TQQQ) increases by 0.6799 to $55.06 with 3,426,778 shares traded, reflecting a 214.63% rise from its 52-week low, showcasing strong demand for tech stocks.
- Individual Stock Outlook: Micron Technology, Inc. (MU) climbs 16.9056 to $353.54 with a volume of 1,816,774 shares, with an expected EPS of $8.18 for the fiscal quarter ending February 2026, indicating improved earnings forecasts.
- Analyst Rating Insights: AT&T Inc. (T) declines by 0.0516 to $23.68 with 2,123,037 shares traded, and Zacks reports its current mean recommendation is in the 'buy range', suggesting analysts are optimistic about its future performance.
See More
BridgeBio Pharma Prices $550M Convertible Notes Offering with $538.4M Net Proceeds Expected
- Offering Size: BridgeBio Pharma has successfully priced a $550M offering of 0.75% convertible senior notes, expected to close on January 21, 2026, indicating strong demand in the capital markets.
- Conversion Terms: Each $1,000 note can be converted into 9.0435 common shares at a conversion price of approximately $110.58, representing a 45% premium over the last closing price of $76.26 on January 15, 2026, providing an attractive option for investors.
- Use of Proceeds: The company plans to utilize approximately $538.4M in net proceeds to repurchase or repay part of its 2.50% convertible notes due 2027, as well as for general corporate purposes including working capital and capital expenditures, enhancing financial flexibility.
- Market Strategy: While targeting over 30% market share for Attruby, BridgeBio Pharma continues to advance its late-stage pipeline, demonstrating ongoing growth potential in the biopharmaceutical sector.
See More
BridgeBio Pharma Prices $550 Million Convertible Notes Offering
- Financing Size: BridgeBio Pharma announced a $550 million offering of 0.75% convertible senior notes, expected to close on January 21, 2026, indicating an active financing strategy in the capital markets.
- Additional Option: The company granted initial purchasers an option to buy an additional $82.5 million in notes, enhancing financing flexibility and potentially supporting future capital needs.
- Use of Net Proceeds: The estimated net proceeds of approximately $538.4 million will be used to repurchase a portion of the 2.50% convertible senior notes due 2027 and for general corporate purposes, reflecting the company's focus on debt management.
- Stock Buyback Plan: BridgeBio intends to use about $82.5 million in cash to repurchase approximately 1.1 million shares of common stock, aimed at enhancing shareholder value and optimizing capital structure, demonstrating confidence in its stock.
See More
BridgeBio Pharma Prices $550 Million Convertible Notes at 0.75% Interest Rate
- Financing Size: BridgeBio Pharma announced the pricing of $550 million in 0.75% convertible notes, expected to close on January 21, 2026, aimed at reducing interest expenses and extending debt maturity.
- Use of Proceeds: The company plans to utilize approximately $538.4 million in net proceeds to repurchase a portion of its 2.50% convertible notes due 2027, enhancing financial flexibility and reducing future dilution risks.
- Share Repurchase Plan: BridgeBio will use about $82.5 million in cash to repurchase approximately 1.1 million shares of common stock, which is expected to boost market prices and may influence the initial conversion price of the notes.
- Conversion Terms: The initial conversion price of the notes is approximately $110.58 per share, representing a 45% premium over the last reported price on January 15, 2026, providing holders with potential capital appreciation opportunities.
See More
BridgeBio Pharma (BBIO) Plans $550 Million Convertible Notes Offering
- Financing Plan: BridgeBio Pharma announced its intention to privately place $550 million of convertible senior notes with qualified institutional buyers, with initial purchasers expected to receive an additional $82.5 million option, thereby enhancing the company's capital structure and liquidity.
- Use of Proceeds: The net proceeds from this offering are intended for repurchasing, settling conversion obligations related to its 2.50% convertible senior notes due 2027, and for general corporate purposes, indicating the company's focus on debt management.
- Share Buyback: BridgeBio also plans to use up to $82.5 million of cash on hand to repurchase shares from certain note purchasers, demonstrating proactive measures in capital allocation to enhance shareholder value.
- Market Reaction: Following the announcement, BridgeBio's stock fell 4.00% in after-hours trading to $74.64, reflecting a cautious market sentiment regarding the financing plan, which may impact investor confidence.
See More
